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Abstract
Background:  Several studies have reported higher rates of antimicrobial resistance among
isolates from intensive care units than among isolates from general patient-care areas. The aims of
this study were to review the pathogens associated with nosocomial infections in a surgical
intensive care unit of a university hospital in Turkey and to summarize rates of antimicrobial
resistance in the most common pathogens. The survey was conducted over a period of twelve
months in a tertiary-care teaching hospital located in the south-eastern part of Turkey, Gaziantep.
A total of 871 clinical specimens from 615 adult patients were collected. From 871 clinical
specimens 771 bacterial and fungal isolates were identified.
Results: Most commonly isolated microorganisms were: Pseudomonas aeruginosa (20.3%), Candida
species (15%) and Staphylococcus aureus (12.9%). Among the Gram-negative microorganisms P.
aeruginosa  were mostly resistant to third-generation cephalosporins (71.3–98.1%), while
Acinetobacter baumannii were resistant in all cases to piperacillin, ceftazidime and ceftriaxone.
Isolates of S. aureus were mostly resistant to penicillin, ampicillin, and methicillin (82–95%), whereas
coagulase-negative staphylococci were 98.6% resistant to methicillin and in all cases resistant to
ampicillin and tetracycline.
Conclusion: In order to reduce the emergence and spread of antimicrobial-resistant pathogens in
ICUs, monitoring and optimization of antimicrobial use in hospitals are strictly recommended.
Therefore local resistance surveillance programs are of most value in developing appropriate
therapeutic guidelines for specific infections and patient types.
Background
Antimicrobial resistance among intensive care unit (ICU)
pathogens is generally increasing, but variations do exist
among different countries, probably due to individual
antimicrobial use patterns. When new medical practices
and alternative antimicrobials are introduced, changes in
the dominant microbial etiologies may emerge prompt-
ing novel empiric selections. Appropriate therapy of ICU
infections directed by local resistance data can have signif-
icant consequences for both patient and the healthcare
system.
Data from National Nosocomial Infections Surveillance
(NNIS) shows that from 1988 to 1995 the number of
intensive care unit (ICU) beds at the hospitals has
increased 17%, whereas total hospital bed capacity
decreased slightly [1]. Patients receiving care in ICUs are
at high risk for nosocomial infections. The emergence of
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antimicrobial-resistant pathogens in ICUs has made treat-
ing these infections very difficult and, in some cases,
impossible. Intensive care unit patients are particularly
susceptible to nosocomial infections due to underlying
illnesses, suppressed immune systems and frequent use of
invasive devices.
This study reviews the pathogens associated with nosoco-
mial infections among ICU patients, summarizes rates of
antimicrobial resistance in the most common pathogens
and provides an overview of strategies to prevent the pro-
liferation of antimicrobial-resistant microorganisms.
Results
During the study period a total of 871 clinical specimens
from 615 adult patients were collected. None of the
patients were receiving immunosuppressive therapy. In
771 (88.5%) of cases the isolate recovered by culture was
confirmed to be the etiologic agent of a nosocomial infec-
tion. The distribution of infections was examined by the
major site of infection. Four major infection sites repre-
sented 91.8% of all reported infections; lower respiratory
tract infections were most frequent (31.5%), followed by
urinary tract infections (27.8%), bloodstream infections
(23.1%) and surgical site infections (9.3%).
The percentages of most frequently isolated microorgan-
isms in ICU were as follows: P. aeruginosa 20.3%, Candida
spp. 15%, S. aureus 12.9%, A. baumannii 9.6%, and coag-
ulase-negative staphylococci 8.9%. In lower respiratory
tract infections, P. aeruginosa (27.9%) was the most com-
monly isolated pathogen, which was followed by S. aureus
(13.6%) and A. baumannii (13.2%). Fifty-seven percent of
reported isolates from the urinary tract were aerobic
Gram-negative bacilli, and in 16.3% of cases Candida spp.
were isolated. Bloodstream infections were mostly caused
S. aureus and coagulase-negative staphylococci with
16.8% and 16.3%, respectively, whereas P. aeruginosa spe-
cies (14.6%) were also frequently isolated from blood. In
surgical site infections S. aureus (23.6%) and P. aeruginosa
(22.2%) were the most commonly isolated infectious
agents (Table 1).
Each of the pathogens listed on Table 1 has demonstrated
antimicrobial resistance to at least one, if not several, of
the antimicrobial agents commonly used to treat infec-
tions caused by these pathogens. In general, Gram-posi-
tive microorganisms such as S. aureus and coagulase-
negative staphylococci were commonly associated with
bloodstream or surgical site infections. Examination of
the rates of antimicrobial resistance among these patho-
gens showed that rates of methicillin-resistant S. aureus
(MRSA) and methicillin-resistant coagulase-negative sta-
phylococci were 82% and 98.6%, respectively (Table 2).
Antimicrobial resistance profiles of MRSA and MSSA
(methicillin-sensitive S. aureus) isolated from infections
in ICU were shown in Table 3.
Gram-negative bacilli are frequently associated with noso-
comial infections in ICU patients (Table 1). Pseudomonas
aeruginosa showed high proportion of resistance against
antipseudomonal penicillins (piperacillin 69.4%, ticarcil-
lin 93%) and third-generation cephalosporins (ceftazi-
dime 71.3%, cefotaxime 96.2%, ceftriaxone 98.1%).
Isolates of A. baumannii were in all cases resistant to ceftri-
axone and in most cases to aztreonam (94.6%) and ticar-
cillin (93.2%). Although Enterobacter  species showed
multiple resistance to most antimicrobials tested, they
were uniformly susceptible to imipenem and cipro-
floxacin.  Klebsiella pneumoniae were usually resistant to
multiple antimicrobials and hydrolized third-generation
cephalosporins and aztreonam (72–88%) (Table 4).
Discussion
A number of factors contribute to the emergence of anti-
microbial resistance in ICUs including the severity of
Table 1: Microorganisms reported from intensive care unit according to the site of infection.
Microorganism Respiratory Tract Urinary Tract Bloodstream Surgical Site Other Sites1
n% n % n % n % n %
Pseudomonas aeruginosa 68 27.9 30 13.9 26 14.6 16 22.2 17 26.9
Staphylococcus aureus 33 13.6 9 4.2 30 16.8 17 23.6 11 17.5
Acinetobacter baumannii 32 13.2 20 9.3 11 6.2 6 8.3 5 7.9
Candida spp. 31 12.8 35 16.3 30 16.8 10 13.9 10 15.8
CN2 – staphylococci 16 6.6 10 4.6 29 16.3 10 13.9 4 6.4
Klebsiella pneumoniae 11 4.5 9 4.2 2 1.1 2 2.8 1 1.6
Enterobacter spp. 10 4.1 13 6.1 6 3.4 2 2.8 1 1.6
Enterococcus spp. 6 2.5 22 10.2 13 7.3 1 1.4 2 3.2
Escherichia coli 3 1.2 27 12.6 4 2.3 3 4.2 1 1.6
Others 33 13.6 40 18.6 27 15.2 5 6.9 11 17.5
Total 243 100 215 100 178 100 72 100 63 100
1 Cerebrospinal fluid, pericardial fluid, peritonal fluid, synovial fluid, biopsy, oral swab, rectal and anal swabs
2 Coagulase-negativeBMC Infectious Diseases 2006, 6:155 http://www.biomedcentral.com/1471-2334/6/155
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patient illness, predisposition to nosocomial infections,
cross-transmission of pathogens characteristic of critical
care areas within the hospital, compromised membrane
and skin barriers following the use of invasive devices,
extended length of hospital stay, and the widespread use
of prophylactic and therapeutic anti-infective agents [2,3].
The types of organisms that have emerged as most prob-
lematic for patients within the ICU include the members
of the family Enterobacteriaceae, non-fermenters (P. aerugi-
nosa and Acinetobacter spp.) oxacillin-resistant S. aureus
and vancomycin-resistant enterococci. All of these resist-
ance profiles have been documented in other regional and
global ICU surveillance studies including Project Inten-
sive Care Antimicrobial Resistance Epidemiology (ICARE,
1994–2000), the Meropenem Yearly Susceptibility Test
Information Collection Program (MYSTIC, 1997–2000),
the ICU Surveillance Study (ISS, 1990–1993, 1994–2000)
and the SENTRY Program (Europe, 1997–1998) [3-8].
The rank order of pathogens recovered in SENTRY Antimi-
crobial Surveillance Program was S. aureus (24.1%), P.
aeruginosa (12.2%), E. coli (10.1%), Klebsiella spp. (8.9%),
Enterococcus spp. (7.2%), coagulase-negative staphyloco-
cci (7%) and Enterobacter spp. (7%) (5). In the MYSTIC
Study, P. aeruginosa (33%) was the most frequent isolate,
followed by A. baumannii (17.1%),  K. pneumoniae
(12.1%), E. coli (10.5%) and E. cloacae (7.9%) (Garcia-
Rodriguez and Jones, 2002). In this study P. aeruginosa
(20.3%) was the most commonly isolated pathogen in
ICU, which was followed by Candida spp. (15%), S. aureus
(12.9%),  A. baumannii (9.6%), and coagulase-negative
staphylococci (8.9%).
Patients in the ICU are more likely than others to be colo-
nized or infected with an antimicrobial-resistant patho-
gen, therefore the rates of resistance are significantly
higher in patients cared for in the ICU than in non-ICU
patients [9-14].
Table 3: Antimicrobial resistances of MRSA and MSSA isolated from infections in ICU.
Percentage (%) of isolates resistant to antimicrobial by broth microdilution
Antimicrobial MRSA1 
n = 82
MSSA2 
n = 18
Vancomycin 0% 0%
Clindamycin 73.2% 66.7%
Erythromycin 90.2% 66.7%
TMP/SMX3 42.7% 22.2%
Ciprofloxacin 79.3% 72.2%
Tetracycline 87.8% 77.7%
1 Methicillin-resistant S. aureus
2 Methicillin-susceptible S. aureus
3 Trimethoprim/sulfamethoxazol
Table 2: Antimicrobial susceptibilities of Gram-positive microorganisms isolated from infections in ICU.
Percentage (%) of isolates resistant to indicated drug by broth microdilution
Antimicrobial S. aureus 
n = 100
CN1 – staphylococci 
n = 69
Enterococcus spp. 
n = 44
Penicillin G 95% 98.6% 84.1%
Ampicillin 95% 100% 77.3%
Amoxicillin/clavulanate 81% 88.4% 77.3%
Methicillin 82% 98.6% 50%
Vancomycin 0% 0% 0%
Clindamycin 72% 66.7% 86.4%
Erythromycin 86% 86.9% 86.4%
TMP/SMX2 39% 100% 75%
Ciprofloxacin 78% 37.7% 81.8%
Tetracycline 86% 100% 84.1%
1 Coagulase-negative
2 Trimethoprim/sulfamethoxazolBMC Infectious Diseases 2006, 6:155 http://www.biomedcentral.com/1471-2334/6/155
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Examination of Gram-positive microorganisms, such as S.
aureus and coagulase-negative staphylococci shows that
rates of methicillin-resistant isolates in ICU have
increased steadily over the past decade [13-15]. In our
study 82% of S. aureus strains and 98.6% of coagulase-
negative staphylococci were resistant to methicillin.
Gram-negative bacilli are frequently associated with noso-
comial infections in ICUs. Data from a multicenter Inten-
sive Care Unit Surveillance Study (ISS) in the United
States demonstrated that resistance to antipseudomonal
agents among ICU isolates of P. aeruginosa, especially
fluoroquinolones, was increasing [16]. The isolates of P.
aeruginosa in this study were resistant 71.4 to 98% to third
generation cephalosporins, and 69.4 to 93% to antipseu-
domonal penicillins. The relatively high susceptibility of
Gram-negative bacilli to fluoroquinolones in this study
can be attributed to antimicrobial prescribing protocol
used in our ICU, which is preferably directed to broad-
spectrum antibiotics.
In recent years Acinetobacter spp. have emerged as impor-
tant pathogens of ICUs, most of them being resistant to
ampicillin, carbenicillin, cefotaxime, chloramphenicol,
and gentamicin [17,18]. In our study, all A. baumannii iso-
lates were resistant to third generation cephalosporins,
and most of them were resistant to aztreonam, ticarcillin,
and gentamicin with 94.6%, 93.2%, and 85.1%, respec-
tively.
Enterobacter species are resistant to first-generation cepha-
losporins and develop antibiotic resistance readily to sec-
ond- and third-generation cephalosporins owing to an
inducible chromosomally encoded cephalosporinase.
Emergence of this form of resistance is seen frequently,
when infection due to these organisms, particularly
Enterobacter cloacae, are treated with broad-spectrum
cephalosporins [19]. Pfaller et al. [20] reported that out of
230 Enterobacter isolates 35–50% were resistant to ceftazi-
dime and piperacillin. In this study the resistance rates of
Enterobacter  strains to third generation cephalosporins
were between 59.4–75%, whereas higher rates were
recorded to aztreonam and gentamicin (both 81.2%).
Another type of commonly seen antimicrobial-resistant
pathogen encountered among ICU patients is Klebsiella
pneumoniae, which is producing extended-spectrum beta-
lactamases (ESBLs). Our isolates of K. pneumoniae showed
high resistance to broad-spectrum cephalosporins and
aztreonam (72–88% and 88%, respectively).
Many studies have demonstrated that the development of
antimicrobial resistance at hospital level is strongly corre-
lated with the use of the relevant antimicrobial [21]. Data
from project ICARE showed that use was significantly
higher among ICU patients than non-ICU patients for
third-generation cephalosporins combined, vancomycin,
anti-pseudomonal penicillin, intravenous fluoroquinolo-
nes and imipenem [22]. This study supports that for each
of the antimicrobial agent used at higher rates in ICU
areas, there was a correspondingly higher rate of the
respective resistant pathogen among ICU patients.
Conclusion
In order to prevent the emergence and spread of antimi-
crobial resistant pathogens in ICU, the pattern of antimi-
crobial use has to be determined. A multidisciplinary
approach is required to succeed in combating the prob-
lem. Hospitals should monitor antimicrobial use to deter-
mine whether specific ICUs or the entire hospital is
overusing antimicrobials. These data could be used, in
conjunction with other related studies, to properly inter-
pret significant resistance patterns and choose the most
appropriate antimicrobial regimens for empirical therapy.
Table 4: Antimicrobial susceptibilities of Gram-negative microorganisms isolated from infections in ICU.
Percentage (%) of isolates resistant to antimicrobial by broth microdilution
Antimicrobial P. aeruginosa 
n = 157
A. baumannii 
n = 74
Enterobacter spp 
n = 32
K. pneumoniae 
n = 25
E. coli 
n = 38
Amikacin 29.9% 71.6% 59.4% 16% 18.4%
Azteronam 77.1% 94.6% 81.2% 88% 86.8%
Piperacillin 69.4% 100% 71.8% 76% 68.4%
Ticarcillin 93% 93.2% 81.2% 64% 68.4%
Ceftriaxone 98.1% 100% 59.4% 84% 84.2%
Cefotaxime 96.2% 100% 59.4% 84% 84.2%
Ceftazidime 71.3% 100% 75% 88% 86.8%
Ciprofloxacin 59.2% 56.7% 0% 20% 39.5%
Imipenem 26.1% 63.5% 0% 12% 13.1%
Cefoperazone 93% 100% 62.5% 72% 86.8%
Gentamicin 48.4% 85.1% 81.2% 80% 78.9%BMC Infectious Diseases 2006, 6:155 http://www.biomedcentral.com/1471-2334/6/155
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Methods
Data were collected from adult patients hospitalized in
the surgical ICU of the Medical Faculty Hospital during
one year period between January and December in 2001.
Standard Centers for Disease Control and Prevention/
NNIS definitions of infection were used [23]. All patients
in the ICU were monitored for nosocomial infection at all
body sites for a period of at least one month. Nosocomial
infections were analyzed by infection site and pathogen
type. Infections were considered ICU-associated if they
developed in the ICU within 48 hours of admission or
within 48 hours of discharge from the ICU. Bloodstream
infection was reported if the patient had either two or
more positive cultures drawn on separate occasions, or
one positive blood culture and treatment was instituted.
The data collected on each infection included the date, site
of infection, age and gender of the patient. Written
informed consent was obtained from all subjects prior to
their inclusion in the study.
Lower respiratory tract specimens included bronchoalveo-
lar lavage, transtracheal aspiration, and pleural fluid. Uri-
nary tract specimens included urine and aspiration from
the urinary catheter. Other types of specimens obtained
from the patients were; swabs from surgical wounds, cer-
ebrospinal fluid, pericardial fluid, peritonal fluid, syno-
vial fluid, biopsy material, oral swab, rectal and anal
swabs. All specimens were collected at the bed site, trans-
ferred to the laboratory immediately and were inoculated
on proper culture media within two hours. Clinical speci-
mens were inoculated onto 5% sheep blood agar, eosine-
methylene-blue agar, Sabouraud's dextrose agar, and
except the urine specimens, onto chocolate agar (Oxoid,
Basingstoke, United Kingdom). Plates were incubated at
37°C in 5% CO2 for 18–24 hours. Methods used for con-
firmation of identification included examination of colo-
nial morphology and haemolytic characteristics on
appropriate agar media, Gram stain, rapid tests (catalase,
oxidase, coagulase, bile solubility, spot indole, latex
agglutination) and use of an automated identification sys-
tem, VITEK (bioMérieux, Marcy-1'Etoile, France), which is
a microbroth dilution method with two wells across pre-
determined breakpoints.
Penicillin G, ampicillin, amoxicillin/clavulanate, methi-
cillin, vancomycin, clindamycin, erythromycin, trimetho-
prim/sulfamethoxazol, ciprofloxacin, and tetracycline
were used for antimicrobnial susceptibility testing. Sus-
ceptibility tests were performed with a commercial broth
microdilution method (VITEK; bioMérieux, Marcy-
1'Etoile, France) according to the manufacturers' guide-
line recommendations and interpretative criteria. Colo-
nies from 18–24 hours old culture medium were used to
inoculate the microdilution plates. Quality control for
testing by VITEK was performed before each new lot of
cards was used. Antimicrobial susceptibilities of the con-
trol microorganisms (S. aureus ATCC 29213, P. aeruginosa
ATCC 27853 and Enterococcus faecalis ATCC 29212) were
performed according to the instructions of CLSI (previ-
ously NCCLS) [24].
All data were stored and analysed using Microsoft Access
and Excel. Statistical analysis was performed using the chi-
squared test for independence and Fisher's exact test
where appropriate. All statisticss were computed using
Scientific Package for Social Sciences (SPSS) software (ver-
sion 11.0; SPSS Inc., Chicago, IL).
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